Developer docs
API playgroundTry for free, no card

Search company profiles

Hildred Capital

Full company profile

uuid000254c

Namestring
Hildred Capital
Legal namestring
Hildred Capital Management, LLC
Websiteurl
hildred.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Hildred Capital Management, LLC is a New York City-based private equity investment firm specializing in lower middle-market healthcare companies. Founded in 2014 by Howard Solomon (former Chairman and CEO of Forest Laboratories), David Solomon (former SVP Corporate Development at Forest Labs), and Andrew Goldman (former CIO at Forest Labs) following the $28 billion sale of Forest Laboratories to Actavis, the firm originally operated as a family office before transitioning to institutional private equity with the launch of Hildred Equity Partners II in 2022. Hildred targets healthcare companies with $10-100 million in revenue, $50-500 million in enterprise value, and makes equity investments of $25-300 million, focused on sub-sectors including healthcare services, infusion, dermatology, medical aesthetics, consumer health, medical devices, diagnostics, and pharma services.

The firm has executed 14 platform investments since inception and manages approximately $4 billion in assets under management, deployed across three institutional vehicles: HEP II ($362.5M, February 2022), a multi-asset continuation fund ($750M+, March 2024, led by Lexington Partners), and HEP III ($800M+, January 2025). Hildred's value creation approach emphasizes operational improvements, organic revenue growth, margin expansion, and M&A support — explicitly avoiding multiple expansion and aggressive leverage as primary return drivers. The firm operates with a lean team of 11-50 employees but oversees more than 3,000 employees across its portfolio companies, applying a proprietary "value creation playbook" and deep industry network cultivated through the founders' Forest Laboratories tenure to source and scale portfolio companies toward strategic exits.

Notable portfolio companies include Tebra (EHR+ platform, $250M financing in December 2025), OrangeTwist (med spa platform, 24 locations across 6 states), AleraCare/Pure Healthcare (national ambulatory infusion platform, 14 states post-merger), SportsMed Physical Therapy (55 outpatient rehab locations), DermCare Management (68+ dermatology practice locations), Crown Laboratories (specialty pharma/dermatology), Butterfly Network (portable ultrasound, taken public via SPAC at ~$1.5B), Pharmaceutics International (CDMO), and Healthcare.com (health insurtech). Hildred is recognized on Inc.'s Founder-Friendly Investors list in both 2024 and 2025, reinforcing its positioning as a partner-of-choice for founder-led healthcare businesses.

Short descriptiontext

Hildred Capital Management is a New York City-based private equity firm that invests $25-300 million in lower middle-market healthcare companies ($10-100M revenue). Founded in 2014 by the former Forest Laboratories leadership team, the firm manages approximately $4 billion in AUM across 14 platform investments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare private equity, growth equity investing, middle-market buyouts, portfolio company management, healthcare sector investing
Industry1 code
PRIMARYFSANACAH
Real Estate / PropTech Growth Equity
NAICS code1 code
  • Finance and Insurance52
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Healthcare Private Equity
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Private Equity Returns
TypeLicensing Royalties
Description

Hildred generates returns through equity ownership in portfolio companies, creating value via operational improvements, strategic growth initiatives, margin expansion, financing, and M&A to drive earnings and cash flow growth. Returns realized through exit events including sales, mergers, and public offerings.

hildred.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Hildred Equity Partners
Description

The firm's private equity fund brand, including HEP I, HEP II, HEP III, and HPP I.

hildred.com
+1 more record
Core offering1 text field

Hildred Capital is a healthcare-focused private equity firm that invests control-oriented equity capital of $25-300 million in lower middle-market healthcare companies with $10-100 million in revenue and $50-500 million in enterprise value. The firm partners with founders and management teams to drive value through operational improvements, organic revenue growth, margin expansion, and M&A initiatives across healthcare services, medical devices, consumer health, pharma services, and aesthetics sub-sectors. Returns are generated through equity ownership and realized via exit events such as strategic sales, mergers, and public offerings.

Differentiator
Functional benefit
Problem solved
Product and service4 records
1Hildred Capital Management - Private Equity Investment Services
CategoryPrivate Equity Investment Management
Description

Healthcare-focused private equity investment management firm providing control-oriented equity capital, operational expertise, and strategic support to lower middle-market healthcare companies with revenues of $10-100 million and enterprise values of $50-500 million. Services include asset identification and selection, value creation through operational improvements, M&A support, and exit strategy execution for portfolio companies and limited partners.

2Hildred Equity Partners II Fund
CategoryPrivate Equity Fund
Description

First institutional private equity fund for healthcare investments with $362.5 million in capital commitments, used to make control-oriented equity investments of $25-300 million in lower middle-market healthcare companies. Limited partners include third-party institutional investors.

3Hildred Multi-Asset Continuation Fund
CategoryContinuation Fund
Description

Multi-asset continuation fund with capital commitments exceeding $750 million, led by Lexington Partners, providing additional capital to support existing portfolio company investments and create a secondary market opportunity for limited partners.

4Hildred Equity Partners III Fund
CategoryPrivate Equity Fund
Description

Third institutional private equity fund with capital commitments exceeding $800 million (oversubscribed), used to make control-oriented equity investments in lower middle-market healthcare companies. Third-party institutional investors participate as limited partners.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-20
Description

Business combination partner for Butterfly Network's NYSE listing via SPAC merger. Transaction valued the company at approximately $1.5 billion.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest and most established healthcare/technology-focused PE firms in the US, with growth equity orientation and a focus on building healthcare leaders. Closely comparable to Hildred in healthcare specialization and lower middle-market orientation.

TypeDirect peer
Description

Growth-oriented PE firm with one of the deepest healthcare focuses in the industry, investing across healthcare services, pharma, and tech-enabled healthcare. Closely comparable to Hildred in sector focus and growth equity approach.

TypeDirect peer
Description

Healthcare-only middle-market PE firm that invests across healthcare services, products, and distribution. Direct competitor for similar deal profiles and portfolio construction strategies as Hildred.

TypeDirect peer
Description

Lower middle-market healthcare PE specialist focused on founder-led and entrepreneur-backed healthcare businesses. Most directly comparable to Hildred on deal size, sector focus, and partnership-driven approach.

TypeDirect peer
Description

Middle-market healthcare-focused PE firm with deep healthcare services and products experience. Comparable in fund size and healthcare specialization to Hildred.

TypeDirect peer
Description

Specialist PE firm focused exclusively on healthcare/life sciences, with similar lower middle-market orientation and growth equity approach. Competes for similar healthcare deal flow as Hildred.

TypeBroad incumbent
Description

KKR's healthcare-dedicated growth equity platform, investing across healthcare services, life sciences, and healthcare tech at scale. Larger and broader than Hildred but directly competes for healthcare growth equity deals.

TypeBroad incumbent
Description

Bain Capital's dedicated life sciences and healthcare investment platform, with significantly larger AUM and broader sector coverage. Competes for healthcare deals and represents the incumbent alternative to specialist firms like Hildred.

TypeBroad incumbent
Description

TPG's dedicated healthcare investment platform spanning services, pharma, and digital health. Larger, broader, and more established than Hildred but with overlapping healthcare deal flow.

TypeDirect peer
Description

Long-tenured healthcare and tech-focused PE firm known for the 'Leaders Strategy' of partnering with executives to build healthcare platforms. Closely comparable in healthcare specialization and operationally-driven value creation approach to Hildred.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hildred Capital

Healthcare Private Equityhildred.com

Hildred Capital Management is a New York City-based private equity firm that invests $25-300 million in lower middle-market healthcare companies ($10-100M revenue). Founded in 2014 by the former Forest Laboratories leadership team, the firm manages approximately $4 billion in AUM across 14 platform investments.

What Hildred Capital does

Hildred Capital Management, LLC is a New York City-based private equity investment firm specializing in lower middle-market healthcare companies. Founded in 2014 by Howard Solomon (former Chairman and CEO of Forest Laboratories), David Solomon (former SVP Corporate Development at Forest Labs), and Andrew Goldman (former CIO at Forest Labs) following the $28 billion sale of Forest Laboratories to Actavis, the firm originally operated as a family office before transitioning to institutional private equity with the launch of Hildred Equity Partners II in 2022. Hildred targets healthcare companies with $10-100 million in revenue, $50-500 million in enterprise value, and makes equity investments of $25-300 million, focused on sub-sectors including healthcare services, infusion, dermatology, medical aesthetics, consumer health, medical devices, diagnostics, and pharma services.

The firm has executed 14 platform investments since inception and manages approximately $4 billion in assets under management, deployed across three institutional vehicles: HEP II ($362.5M, February 2022), a multi-asset continuation fund ($750M+, March 2024, led by Lexington Partners), and HEP III ($800M+, January 2025). Hildred's value creation approach emphasizes operational improvements, organic revenue growth, margin expansion, and M&A support — explicitly avoiding multiple expansion and aggressive leverage as primary return drivers. The firm operates with a lean team of 11-50 employees but oversees more than 3,000 employees across its portfolio companies, applying a proprietary "value creation playbook" and deep industry network cultivated through the founders' Forest Laboratories tenure to source and scale portfolio companies toward strategic exits.

Notable portfolio companies include Tebra (EHR+ platform, $250M financing in December 2025), OrangeTwist (med spa platform, 24 locations across 6 states), AleraCare/Pure Healthcare (national ambulatory infusion platform, 14 states post-merger), SportsMed Physical Therapy (55 outpatient rehab locations), DermCare Management (68+ dermatology practice locations), Crown Laboratories (specialty pharma/dermatology), Butterfly Network (portable ultrasound, taken public via SPAC at ~$1.5B), Pharmaceutics International (CDMO), and Healthcare.com (health insurtech). Hildred is recognized on Inc.'s Founder-Friendly Investors list in both 2024 and 2025, reinforcing its positioning as a partner-of-choice for founder-led healthcare businesses.

Hildred Capital firmographics

Firmographics
Name
Hildred Capital
Legal name
Hildred Capital Management, LLC
Website
https://hildred.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Hildred Capital Management is a New York City-based private equity firm that invests $25-300 million in lower middle-market healthcare companies ($10-100M revenue). Founded in 2014 by the former Forest Laboratories leadership team, the firm manages approximately $4 billion in AUM across 14 platform investments.
Ownership category
akta.pro rank

Hildred Capital industry classification

Industry
Product category
Healthcare Private Equity
NAICS
Finance and Insurance (52)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSANACAH
Real Estate / PropTech Growth Equity

Keywords

  • Healthcare private equity
  • Growth equity investing
  • Middle-market buyouts
  • Portfolio company management
  • Healthcare sector investing

Where Hildred Capital is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Hildred Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Private Equity Returns: Hildred generates returns through equity ownership in portfolio companies, creating value via operational improvements, strategic growth initiatives, margin expansion, financing, and M&A to drive earnings and cash flow growth. Returns realized through exit events including sales, mergers, and public offerings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Hildred Capital product offering

Product offering

Core offering

Hildred Capital is a healthcare-focused private equity firm that invests control-oriented equity capital of $25-300 million in lower middle-market healthcare companies with $10-100 million in revenue and $50-500 million in enterprise value. The firm partners with founders and management teams to drive value through operational improvements, organic revenue growth, margin expansion, and M&A initiatives across healthcare services, medical devices, consumer health, pharma services, and aesthetics sub-sectors. Returns are generated through equity ownership and realized via exit events such as strategic sales, mergers, and public offerings.

Differentiator

Problem solved

Functional benefit

Brands

  • Hildred Equity Partners: The firm's private equity fund brand, including HEP I, HEP II, HEP III, and HPP I.
  • Hildred Capital Partners

Products and services

  • Hildred Capital Management - Private Equity Investment Services Healthcare-focused private equity investment management firm providing control-oriented equity capital, operational expertise, and strategic support to lower middle-market healthcare companies with revenues of $10-100 million and enterprise values of $50-500 million. Services include asset identification and selection, value creation through operational improvements, M&A support, and exit strategy execution for portfolio companies and limited partners.
  • Hildred Equity Partners II Fund First institutional private equity fund for healthcare investments with $362.5 million in capital commitments, used to make control-oriented equity investments of $25-300 million in lower middle-market healthcare companies. Limited partners include third-party institutional investors.
  • Hildred Multi-Asset Continuation Fund Multi-asset continuation fund with capital commitments exceeding $750 million, led by Lexington Partners, providing additional capital to support existing portfolio company investments and create a secondary market opportunity for limited partners.
  • Hildred Equity Partners III Fund Third institutional private equity fund with capital commitments exceeding $800 million (oversubscribed), used to make control-oriented equity investments in lower middle-market healthcare companies. Third-party institutional investors participate as limited partners.

Companies that use Hildred Capital

Customer profile

Named customers14 records

Segments1 record

Ideal customer profiles1 record

Hildred Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Hildred Capital partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Longview Acquisition Corp.coreStrategic or Co-development Partner · 20 November 2020Business combination partner for Butterfly Network's NYSE listing via SPAC merger. Transaction valued the company at approximately $1.5 billion.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Hildred Capital competitors and assessment

Company assessment

Direct peers

  • Welsh, Carson, Anderson & Stowe: One of the largest and most established healthcare/technology-focused PE firms in the US, with growth equity orientation and a focus on building healthcare leaders. Closely comparable to Hildred in healthcare specialization and lower middle-market orientation.
  • New Mountain Capital: Growth-oriented PE firm with one of the deepest healthcare focuses in the industry, investing across healthcare services, pharma, and tech-enabled healthcare. Closely comparable to Hildred in sector focus and growth equity approach.
  • Linden Capital Partners: Healthcare-only middle-market PE firm that invests across healthcare services, products, and distribution. Direct competitor for similar deal profiles and portfolio construction strategies as Hildred.
  • Varsity Healthcare Partners: Lower middle-market healthcare PE specialist focused on founder-led and entrepreneur-backed healthcare businesses. Most directly comparable to Hildred on deal size, sector focus, and partnership-driven approach.
  • Avista Capital Partners: Middle-market healthcare-focused PE firm with deep healthcare services and products experience. Comparable in fund size and healthcare specialization to Hildred.
  • Ampersand Capital Partners: Specialist PE firm focused exclusively on healthcare/life sciences, with similar lower middle-market orientation and growth equity approach. Competes for similar healthcare deal flow as Hildred.
  • GTCR: Long-tenured healthcare and tech-focused PE firm known for the 'Leaders Strategy' of partnering with executives to build healthcare platforms. Closely comparable in healthcare specialization and operationally-driven value creation approach to Hildred.

Broad incumbents

  • KKR (Healthcare Strategic Growth): KKR's healthcare-dedicated growth equity platform, investing across healthcare services, life sciences, and healthcare tech at scale. Larger and broader than Hildred but directly competes for healthcare growth equity deals.
  • Bain Capital Life Sciences: Bain Capital's dedicated life sciences and healthcare investment platform, with significantly larger AUM and broader sector coverage. Competes for healthcare deals and represents the incumbent alternative to specialist firms like Hildred.
  • TPG (Capital Healthcare): TPG's dedicated healthcare investment platform spanning services, pharma, and digital health. Larger, broader, and more established than Hildred but with overlapping healthcare deal flow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Hildred Capital social profiles

Digital presence

Hildred Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hildred Capital leadership team

Management profile

Number of profiles

Profiles8 records

Hildred Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hildred Capital M&A and investment

M&A and investment

M&A1 record

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hildred Capital

What does Hildred Capital do?

Hildred Capital is a healthcare-focused private equity firm that invests control-oriented equity capital of $25-300 million in lower middle-market healthcare companies with $10-100 million in revenue and $50-500 million in enterprise value. The firm partners with founders and management teams to drive value through operational improvements, organic revenue growth, margin expansion, and M&A initiatives across healthcare services, medical devices, consumer health, pharma services, and aesthetics sub-sectors. Returns are generated through equity ownership and realized via exit events such as strategic sales, mergers, and public offerings.

Is Hildred Capital a public or private company?

Hildred Capital is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hildred Capital founded?

Hildred Capital was founded in 2014. It employs 11 to 50 people.

Where is Hildred Capital based?

Hildred Capital is headquartered in New York, United States, in the North America region.

How does Hildred Capital make money?

One revenue line is on record: private Equity Returns.

Who are Hildred Capital's main competitors?

Direct peers on record are Welsh, Carson, Anderson & Stowe, New Mountain Capital, Linden Capital Partners, Varsity Healthcare Partners, Avista Capital Partners, Ampersand Capital Partners and GTCR. Broad incumbents are KKR (Healthcare Strategic Growth), Bain Capital Life Sciences and TPG (Capital Healthcare).

Does Hildred Capital have an API?

No public API is recorded for Hildred Capital.

What industry is Hildred Capital in?

Hildred Capital's product category is Healthcare Private Equity. Its primary akta.pro industry code is FSANACAH, Real Estate / PropTech Growth Equity. Its NAICS code is 52 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogHildred Named to Inc.’s List of Founder-Friendly Investors for Third Consecutive YearHildred, a healthcare private equity firm, was named to Inc.'s 2026 Founder-Friendly Investors list for the third consecutive year. The firm manages approximately $5 billion in assets and has worked with founders to transform middle-market healthcare companies. Inc. compiled the list from entrepreneurs who sold to private equity and venture capital firms.The Dallas Morning NewsKristen Bell-founded brand cuts jobs, ends Texas diaper productionHello Bello, founded by Kristen Bell and Dax Shepard, is ending diaper production in Waco and transitioning the facility to a distribution center, cutting 67 jobs starting Nov. 27. The brand, which declared bankruptcy in 2023, was acquired by Hildred Capital Management. Two other companies in the D-FW area are also cutting jobs.PitchBookHealthcare funds are winning the fight for investor dollarsHealthcare buyout funds raised 4.2% less capital in 2025 than generalist funds, but still outperformed the broader PE market. 75.8% of healthcare funds hit their targets, versus 72.6% for generalist funds. Investors are increasingly backing specialist managers and mega-funds.The SaaS NewsTebra Secures $250 Million in FundingTebra, a Newport Beach, CA-based all-in-one EHR+ platform, has secured $250 million in equity and debt financing. The funding, led by Hildred with participation from J.P. Morgan and other investors, will be used to enhance Tebra's AI-powered capabilities across its platform. This investment aims to improve services for over 140,000 private healthcare providers across more than 42,000 independent practices.Business Wire BlogHildred Named to Inc.’s 2025 List of Founder-Friendly InvestorsHildred, a healthcare-focused private equity firm, has been named to Inc.'s 2025 Founder-Friendly Investors list, which recognizes investors committed to backing founder-led businesses. The list was compiled based on feedback from entrepreneurs who have sold to private equity and venture capital firms, with founders providing data on their experiences and company growth during these partnerships. Hildred's co-founders stated the recognition reflects their commitment to acting as trusted partners to portfolio companies and helping them achieve strategic objectives.Financial TimesSignet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. Announce Exit from Pharmaceutics International, Inc. – Company AnnouncementA consortium led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Inc. exited its stake in Pharmaceutics International, Inc. and sold the contract development and manufacturing organization to Jabil Inc. in an undisclosed all-cash transaction. Pii, based in Hunt Valley, Maryland, specializes in aseptic and sterile injectable pharmaceutical products.Stock TitanJabil Acquires Sterile Injectables Manufacturer Pii in Strategic Pharma ExpansionA consortium of investors led by Signet Healthcare Partners, Athyrium Capital, Hildred Capital, and Pharmascience Inc. exited their stake in Pii, a sterile injectables CDMO, and sold it to Jabil in an all-cash deal. Pii, based in Hunt Valley, Maryland, has served pharmaceutical clients for nearly three decades. The company will now operate under Jabil's ownership.WsjExclusive | Hildred Capital Doubles Down on Healthcare Deals With $810 Million FundHildred Capital Management closed an institutional fund focused on small and midsize healthcare businesses after raising $810 million, more than double the $363 million raised for a predecessor vehicle. The firm committed over $60 million to Hildred Equity Partners III and raised about $750 million from other investors, broadening its overseas investor base.Pulse 2.0Hildred Capital: Multi-Asset Continuation Fund Closed With Commitments Of Over $750 MillionHildred Capital closed a $750 million multi-asset continuation fund led by Lexington Partners to buy two healthcare consumer product companies. The fund includes unfunded capital for organic growth and strategic acquisitions, with co-founders rolling over 100% of their interests.Lowenstein Sandler LLPLowenstein Represents Hildred Capital in $750M Continuation Fund Extending Ownership of Portfolio Companies, Hyland’s Naturals and Crown LaboratoriesLowenstein Sandler represented private equity firm Hildred Capital in raising $750 million for a continuation fund to extend ownership of portfolio companies Hyland’s Naturals and Crown Laboratories. The funding allows Hildred to maintain control over these healthcare-focused assets and potentially finance future acquisitions by the subsidiaries.